• Explore /
  • Poster
  • / A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

Abstract Poster

Authors

null

Jian-Ming Xu

The Fifth Medical Center, People’s Liberation Army General Hospital, Beijing, China

Jian-Ming Xu , Ken Kato , Richard Hubner , Eric Raymond , Yihuan Xu , Sumei Liu , Ibrahim Qazi , Harry H. Yoon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03783442

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2656)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2656

Abstract #

TPS2656

Poster Bd #

294a

Abstract Disclosures

Similar Posters

First Author: Harry H. Yoon

First Author: Deirdre Jill Cohen

First Author: Rui-hua Xu

First Author: Hendrik-Tobias Arkenau